Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: A multicenter, international experience of 248 patients (IELSG 41)

Amie E. Jackson, Michael Mian, Christina Kalpadakis, Gerassimos A. Pangalis, Anastasios Stathis, Elena Porro, Annarita Conconi, Sergio Cortelazzo, Gianluca Gaidano, Armando Lopez Guillermo, Peter W. Johnson, Maurizio Martelli, Giovanni Martinelli, Catherine Thieblemont, Ellen D. McPhail, Christiane Copie-Bergman, Stefano A. Pileri, Andrew Jack, Elias Campo, Luca MazzucchelliKay Ristow, Thomas M. Habermann, Franco Cavalli, Grzegorz S. Nowakowski, Emanuele Zucca

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background. The salivary gland is one of the most common sites involved by nongastric, extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). A large series of patients with long-term follow-up has not been documented. This multicenter, international study sought to characterize the clinical characteristics, treatment, and natural history of salivary gland MALT lymphoma. Methods. Patients with biopsy-confirmed salivary gland MALT lymphoma were identified from multiple international sites. Risk factors, treatment, and long-term outcomes were evaluated. Results. A total of 247 patients were evaluated; 76% presented with limited-stage disease. There was a history of autoimmune disorder in 41%, with Sjögren disease being the most common (83%). Fifty-seven percent of patients were initially treated with local therapy with surgery, radiation, or both; 37 of patients were treated with systemic therapy initially, with 47% of those receiving rituximab; and 6% of patients were observed. The median overall survival (OS) was 18.3 years. The median progression-free survival (PFS) following primary therapy was 9.3 years. There was no difference in the outcomes between patients receiving local or systemic therapy in first-line management. On multivariate analysis, age

Original languageEnglish
Pages (from-to)1149-1153
Number of pages5
JournalThe oncologist
Volume20
Issue number10
DOIs
Publication statusPublished - Aug 12 2015

Fingerprint

Marginal Zone B-Cell Lymphoma
Salivary Glands
Therapeutics
Natural History
Multicenter Studies
Disease-Free Survival
Multivariate Analysis
Radiation
Biopsy
Survival

Keywords

  • B-cell
  • Lymphoid tissue
  • Lymphoma
  • Marginal zone
  • Salivary glands
  • Sjögren’s disease

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands : A multicenter, international experience of 248 patients (IELSG 41). / Jackson, Amie E.; Mian, Michael; Kalpadakis, Christina; Pangalis, Gerassimos A.; Stathis, Anastasios; Porro, Elena; Conconi, Annarita; Cortelazzo, Sergio; Gaidano, Gianluca; Guillermo, Armando Lopez; Johnson, Peter W.; Martelli, Maurizio; Martinelli, Giovanni; Thieblemont, Catherine; McPhail, Ellen D.; Copie-Bergman, Christiane; Pileri, Stefano A.; Jack, Andrew; Campo, Elias; Mazzucchelli, Luca; Ristow, Kay; Habermann, Thomas M.; Cavalli, Franco; Nowakowski, Grzegorz S.; Zucca, Emanuele.

In: The oncologist, Vol. 20, No. 10, 12.08.2015, p. 1149-1153.

Research output: Contribution to journalArticle

Jackson, AE, Mian, M, Kalpadakis, C, Pangalis, GA, Stathis, A, Porro, E, Conconi, A, Cortelazzo, S, Gaidano, G, Guillermo, AL, Johnson, PW, Martelli, M, Martinelli, G, Thieblemont, C, McPhail, ED, Copie-Bergman, C, Pileri, SA, Jack, A, Campo, E, Mazzucchelli, L, Ristow, K, Habermann, TM, Cavalli, F, Nowakowski, GS & Zucca, E 2015, 'Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: A multicenter, international experience of 248 patients (IELSG 41)', The oncologist, vol. 20, no. 10, pp. 1149-1153. https://doi.org/10.1634/theoncologist.2015-0180
Jackson, Amie E. ; Mian, Michael ; Kalpadakis, Christina ; Pangalis, Gerassimos A. ; Stathis, Anastasios ; Porro, Elena ; Conconi, Annarita ; Cortelazzo, Sergio ; Gaidano, Gianluca ; Guillermo, Armando Lopez ; Johnson, Peter W. ; Martelli, Maurizio ; Martinelli, Giovanni ; Thieblemont, Catherine ; McPhail, Ellen D. ; Copie-Bergman, Christiane ; Pileri, Stefano A. ; Jack, Andrew ; Campo, Elias ; Mazzucchelli, Luca ; Ristow, Kay ; Habermann, Thomas M. ; Cavalli, Franco ; Nowakowski, Grzegorz S. ; Zucca, Emanuele. / Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands : A multicenter, international experience of 248 patients (IELSG 41). In: The oncologist. 2015 ; Vol. 20, No. 10. pp. 1149-1153.
@article{a1f7eca1d5ae4aa29869653afe36b0f5,
title = "Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: A multicenter, international experience of 248 patients (IELSG 41)",
abstract = "Background. The salivary gland is one of the most common sites involved by nongastric, extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). A large series of patients with long-term follow-up has not been documented. This multicenter, international study sought to characterize the clinical characteristics, treatment, and natural history of salivary gland MALT lymphoma. Methods. Patients with biopsy-confirmed salivary gland MALT lymphoma were identified from multiple international sites. Risk factors, treatment, and long-term outcomes were evaluated. Results. A total of 247 patients were evaluated; 76{\%} presented with limited-stage disease. There was a history of autoimmune disorder in 41{\%}, with Sj{\"o}gren disease being the most common (83{\%}). Fifty-seven percent of patients were initially treated with local therapy with surgery, radiation, or both; 37 of patients were treated with systemic therapy initially, with 47{\%} of those receiving rituximab; and 6{\%} of patients were observed. The median overall survival (OS) was 18.3 years. The median progression-free survival (PFS) following primary therapy was 9.3 years. There was no difference in the outcomes between patients receiving local or systemic therapy in first-line management. On multivariate analysis, age",
keywords = "B-cell, Lymphoid tissue, Lymphoma, Marginal zone, Salivary glands, Sj{\"o}gren’s disease",
author = "Jackson, {Amie E.} and Michael Mian and Christina Kalpadakis and Pangalis, {Gerassimos A.} and Anastasios Stathis and Elena Porro and Annarita Conconi and Sergio Cortelazzo and Gianluca Gaidano and Guillermo, {Armando Lopez} and Johnson, {Peter W.} and Maurizio Martelli and Giovanni Martinelli and Catherine Thieblemont and McPhail, {Ellen D.} and Christiane Copie-Bergman and Pileri, {Stefano A.} and Andrew Jack and Elias Campo and Luca Mazzucchelli and Kay Ristow and Habermann, {Thomas M.} and Franco Cavalli and Nowakowski, {Grzegorz S.} and Emanuele Zucca",
year = "2015",
month = "8",
day = "12",
doi = "10.1634/theoncologist.2015-0180",
language = "English",
volume = "20",
pages = "1149--1153",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "10",

}

TY - JOUR

T1 - Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands

T2 - A multicenter, international experience of 248 patients (IELSG 41)

AU - Jackson, Amie E.

AU - Mian, Michael

AU - Kalpadakis, Christina

AU - Pangalis, Gerassimos A.

AU - Stathis, Anastasios

AU - Porro, Elena

AU - Conconi, Annarita

AU - Cortelazzo, Sergio

AU - Gaidano, Gianluca

AU - Guillermo, Armando Lopez

AU - Johnson, Peter W.

AU - Martelli, Maurizio

AU - Martinelli, Giovanni

AU - Thieblemont, Catherine

AU - McPhail, Ellen D.

AU - Copie-Bergman, Christiane

AU - Pileri, Stefano A.

AU - Jack, Andrew

AU - Campo, Elias

AU - Mazzucchelli, Luca

AU - Ristow, Kay

AU - Habermann, Thomas M.

AU - Cavalli, Franco

AU - Nowakowski, Grzegorz S.

AU - Zucca, Emanuele

PY - 2015/8/12

Y1 - 2015/8/12

N2 - Background. The salivary gland is one of the most common sites involved by nongastric, extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). A large series of patients with long-term follow-up has not been documented. This multicenter, international study sought to characterize the clinical characteristics, treatment, and natural history of salivary gland MALT lymphoma. Methods. Patients with biopsy-confirmed salivary gland MALT lymphoma were identified from multiple international sites. Risk factors, treatment, and long-term outcomes were evaluated. Results. A total of 247 patients were evaluated; 76% presented with limited-stage disease. There was a history of autoimmune disorder in 41%, with Sjögren disease being the most common (83%). Fifty-seven percent of patients were initially treated with local therapy with surgery, radiation, or both; 37 of patients were treated with systemic therapy initially, with 47% of those receiving rituximab; and 6% of patients were observed. The median overall survival (OS) was 18.3 years. The median progression-free survival (PFS) following primary therapy was 9.3 years. There was no difference in the outcomes between patients receiving local or systemic therapy in first-line management. On multivariate analysis, age

AB - Background. The salivary gland is one of the most common sites involved by nongastric, extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). A large series of patients with long-term follow-up has not been documented. This multicenter, international study sought to characterize the clinical characteristics, treatment, and natural history of salivary gland MALT lymphoma. Methods. Patients with biopsy-confirmed salivary gland MALT lymphoma were identified from multiple international sites. Risk factors, treatment, and long-term outcomes were evaluated. Results. A total of 247 patients were evaluated; 76% presented with limited-stage disease. There was a history of autoimmune disorder in 41%, with Sjögren disease being the most common (83%). Fifty-seven percent of patients were initially treated with local therapy with surgery, radiation, or both; 37 of patients were treated with systemic therapy initially, with 47% of those receiving rituximab; and 6% of patients were observed. The median overall survival (OS) was 18.3 years. The median progression-free survival (PFS) following primary therapy was 9.3 years. There was no difference in the outcomes between patients receiving local or systemic therapy in first-line management. On multivariate analysis, age

KW - B-cell

KW - Lymphoid tissue

KW - Lymphoma

KW - Marginal zone

KW - Salivary glands

KW - Sjögren’s disease

UR - http://www.scopus.com/inward/record.url?scp=84943276711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943276711&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2015-0180

DO - 10.1634/theoncologist.2015-0180

M3 - Article

AN - SCOPUS:84943276711

VL - 20

SP - 1149

EP - 1153

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -